Novartis signs up to $7.8 billion Abogen licensing deal — Eter News

Enriched Analysis 深度解析

Novartis signs up to $7.8 billion Abogen licensing dealNovartis签署最高78亿美元的Abogen授权协议

Novartis will pay $575 million upfront for global rights to Abogen Biosciences’ early-stage messenger RNA therapy for autoimmune disease, with up to $7.2 billion in milestone payments. The agreement adds to a growing series of licensing deals between global pharmaceutical companies and Chinese biotechs, as drugmakers seek new assets ahead of major patent expirations in the early 2030s.Novartis将为Abogen Biosciences一款用于自身免疫性疾病的早期信使RNA疗法全球权益支付5.75亿美元首付款，并提供最高72亿美元的里程碑付款。该协议加入了全球制药公司与中国生物科技企业之间日益增多的授权交易，药企正寻求新资产，以应对2030年代初的重要专利到期。

cnbc.com 2 Oct 2026 2026年10月2日

575575

Upfront payment首付款

3333

China’s share of new molecules in global pipelines中国占全球研发管线中新分子的比例

01The Story新闻事实

Novartis will pay $575 million upfront for global rights to Abogen Biosciences’ early-stage messenger RNA therapy for autoimmune disease, with up to $7.2 billion in milestone payments. The agreement adds to a growing series of licensing deals between global pharmaceutical companies and Chinese biotechs, as drugmakers seek new assets ahead of major patent expirations in the early 2030s.Novartis将为Abogen Biosciences一款用于自身免疫性疾病的早期信使RNA疗法全球权益支付5.75亿美元首付款，并提供最高72亿美元的里程碑付款。该协议加入了全球制药公司与中国生物科技企业之间日益增多的授权交易，药企正寻求新资产，以应对2030年代初的重要专利到期。

  • Novartis will pay $575 million upfront and up to $7.2 billion in milestone payments for the global rights to Abogen’s messenger RNA therapy.Novartis将为Abogen信使RNA疗法的全球权益支付5.75亿美元首付款，另加最高72亿美元的里程碑付款。
  • The therapy is an early-stage experimental treatment for autoimmune disease.这款疗法是一种用于自身免疫性疾病的早期试验性治疗方法。
  • Novartis will also have an exclusive option to license assets developed on Abogen’s RNA platform.Novartis还将获得独家选择权，可授权Abogen基于RNA平台开发的其他资产。
  • ING estimates that China will account for about a third of all new molecules in global pharmaceutical pipelines in 2026, up from 4% in 2014.ING估计，2026年中国将约占全球制药企业研发管线中新分子的三分之一，高于2014年的4%。
  • ING expects the value of Chinese biotech outlicensing deals to exceed $250 billion in 2026.ING预计，2026年中国生物科技企业对外授权交易的价值将超过2500亿美元。

The deal shows how licensing is becoming a key channel for global drugmakers to access Chinese biotech assets while limiting the risks of outright acquisitions.这笔交易显示，授权正成为全球药企获取中国生物科技资产的重要渠道，同时降低直接收购带来的风险。

023 Dimensions维度分析

Stakeholder impact利益相关方

Deal structure交易结构

Most of the potential value is tied to future milestones rather than the upfront payment. This structure gives Novartis access to the asset while allowing payments to depend on development progress.交易的大部分潜在价值取决于未来里程碑，而不是首付款。这种结构让Novartis能够获得资产，同时使付款与研发进展挂钩。

Upfront payment首付款

20262026年575 million USD

20262026年7,200 million USD

  • The total deal value is up to $7.8 billion.交易总价值最高可达78亿美元。
  • Novartis receives an exclusive option to license additional assets from Abogen’s RNA platform.Novartis获得授权Abogen RNA平台其他资产的独家选择权。
Future signal前瞻信号

China’s growing biotech role中国生物科技行业影响力上升

The Abogen agreement is part of a broader flow of Chinese biotech assets into global pharmaceutical development programs. ING’s estimates indicate a sharp increase in China’s contribution to new drug molecules and outlicensing activity.Abogen协议是中国生物科技资产进入全球制药研发项目这一更大趋势的一部分。ING的估计显示，中国对新药分子和对外授权活动的贡献正在显著增加。

China’s share of new molecules in global pipelines中国占全球研发管线中新分子的比例

20262026年33 %

20262026年250 billion USD

  • ING estimates that China will account for about one-third of new molecules in global pharmaceutical pipelines in 2026.ING估计，2026年中国将约占全球制药研发管线中新分子的三分之一。
  • Faster and cheaper early-stage clinical development was cited as one factor helping Chinese biotechs attract global drugmakers.报道提到，更快且成本更低的早期临床开发，是帮助中国生物科技企业吸引全球药企的因素之一。
Cause因果关系

Patent-expiry pressure专利到期压力

Global drugmakers are seeking new medicines as patents on top-selling products face a patent cliff in the early 2030s. Novartis has also faced recent clinical setbacks, increasing the importance of finding and developing replacement assets.随着畅销药物专利在2030年代初面临集中到期，全球药企正在寻找新药。Novartis近期还遭遇临床试验挫折，这提高了寻找和开发替代资产的重要性。

  • The source says patents on top-selling drugs face a patent cliff in the early 2030s.报道称，畅销药物的专利将在2030年代初面临集中到期。
  • Novartis’ shares fell last month by the most since 1987 following several clinical trial setbacks, according to the source.报道称，Novartis股价上月因数项临床试验受挫，录得自1987年以来最大跌幅。

03Timeline时间线

  1. 2026-09 GSK said it was acquiring a blood cancer medicine from Chinese biotech Chimagen Biosciences for up to $750 million.GSK表示将以最高7.5亿美元收购中国生物科技公司Chimagen Biosciences的一款血癌药物。
  2. 2026-10-02 Novartis announced its licensing agreement with Abogen Biosciences.Novartis宣布与Abogen Biosciences达成授权协议。

Key takeaway核心结论

Novartis’ Abogen deal reflects the growing use of licensing to connect Chinese biotech innovation with global pharmaceutical development.Novartis与Abogen的交易反映出，授权正日益成为连接中国生物科技创新与全球制药研发的方式。

04What to Watch后续关注

  1. Whether Abogen’s early-stage autoimmune disease therapy advances successfully through clinical development.Abogen这款自身免疫性疾病早期疗法能否顺利推进临床开发。
  2. Whether Novartis exercises its exclusive option to license additional assets from Abogen’s RNA platform.Novartis是否会行使权利，授权Abogen RNA平台的其他资产。
  3. Whether further licensing agreements bring more Chinese biotech assets into global pharmaceutical pipelines.是否会有更多授权协议将中国生物科技资产纳入全球制药研发管线。
  4. How pharmaceutical companies respond to patent expirations expected in the early 2030s.制药企业将如何应对预计在2030年代初出现的专利到期。

05Uncertainties不确定因素

  • The treatment is still at an early experimental stage, so its clinical performance and regulatory outcome remain unknown.该疗法仍处于早期试验阶段，其临床表现和监管结果尚未确定。
  • The $7.2 billion milestone component depends on future development milestones and is not an upfront payment.72亿美元的里程碑付款取决于未来研发节点，并非首付款。
  • The source does not specify the terms or expiry of Novartis’ exclusive option over additional RNA-platform assets.消息来源未说明Novartis对其他RNA平台资产独家选择权的具体条款或期限。

06Sources信息来源

  1. Novartis signs $7.8 billion Abogen biotech licensing dealNovartis signs $7.8 billion Abogen biotech licensing deal cnbc.com · 2026-10-02

Share this analysis 分享此深度分析

X Facebook LinkedIn WhatsApp